Clinical Focus
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants priority review to sBLA for EV plus pembrolizumab in cisplatin-ineligible MIBC
2
Kim Nguyen Chi, MD, on 177Lu-PSMA-617 vs docetaxel in mCRPC
3
Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS
4
News Network: Prostate Cancer and Bladder Cancer at ESMO 2025
5
